Kiniksa Pharmaceuticals, Ltd. — Q1 2019 Form 10-Q
Reporting period: Three months ended March 31, 2019; comparative period is Q1 2018. The filing identifies the registrant as Kiniksa Pharmaceuticals, Ltd. (Bermuda), rather than “International, Plc.” Kiniksa is a clinical-stage biopharmaceutical company developing therapies for autoinflammatory and autoimmune diseases. It had no approved products and generated no product revenue.
Financial performance and liquidity
Amounts below are in U.S. dollars; financial statement figures are rounded to millions.
| Metric | Q1 2019 | Q1 2018 / comparison |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $59.3 million | $12.6 million |
| General and administrative expense | $8.4 million | $3.7 million |
| Total operating expenses | $67.6 million | $16.3 million |
| Interest income | $1.8 million | $0.3 million |
| Net loss | $65.8 million | $16.0 million |
| Net loss per share, basic and diluted | $1.27 | $6.45; weighted-average shares increased substantially after the IPO |
| Cash used in operating activities | $63.3 million | $15.0 million |
| Cash provided by financing activities | $83.2 million | $190.8 million |
Margins are not meaningful because the company reported no revenue. At March 31, 2019, cash and cash equivalents were $82.6 million and short-term investments were $243.9 million, for combined liquidity of $326.5 million. Current assets were $335.0 million and current liabilities $36.9 million. The accumulated deficit was $260.0 million. The filing reports no debt balance; liabilities primarily comprise accounts payable, accruals, milestone obligations and operating lease liabilities. Total operating lease liabilities were $3.6 million.
Material changes and notable items
- Net loss increased by $49.8 million year over year, mainly reflecting increased development spending, the Primatope acquisition and a Biogen clinical milestone.
- R&D included $18.0 million related to acquiring Primatope and $10.0 million accrued for a Biogen milestone under the KPL-716 agreement. The Primatope amount included $10.0 million upfront, $5.0 million in achieved milestones, and $3.0 million accrued as probable and estimable. The acquisition was accounted for as an asset acquisition, with the costs expensed as in-process R&D.
- The company completed a February follow-on offering and concurrent private placement, including partial exercise of the over-allotment option. Net proceeds were approximately $83.0 million. The financing explains the increase in cash and equity, alongside the operating cash burn.
- The company adopted lease accounting standard ASC 842 on January 1, 2019, recording lease right-of-use assets and liabilities.
Outlook, risks and contingencies
- Management expected existing cash, cash equivalents and short-term investments to fund operating expenses and capital expenditures for at least 12 months from the financial statements’ issuance date. The company expects continuing losses and says funding beyond that period depends on raising additional capital; the estimate is subject to assumptions and may prove insufficient.
- Management expected R&D expenses to increase as trials advance, including publicized expectations for RHAPSODY Phase 3 rilonacept top-line results in the second half of 2020; rilonacept Phase 2 completion in the second half of 2019; mavrilimumab Phase 2 top-line data in the second half of 2020; and KPL-716 prurigo nodularis Phase 2a data in the first half of 2020. KPL-404 IND filing was expected in the second half of 2019, with a Phase 1 trial planned for the first half of 2020. These are forward-looking expectations, not reported outcomes.
- Key risks include clinical failure or delays, regulatory uncertainty, adverse events, manufacturing and single-source supplier dependence, patient enrollment, competition, intellectual-property disputes, reimbursement and the need for further financing. Management noted FDA feedback that mavrilimumab’s benefit-risk assessment in GCA may require evidence beyond the 26-week Phase 2 dosing period.
- Committed minimum payments to contract manufacturers totaled $10.9 million at quarter-end. License agreements include substantial contingent clinical, regulatory and sales milestones and potential royalties. No material litigation or litigation reserves were reported; the company was not party to material legal proceedings.
- Class B shares carry ten votes each; Class A1 and B1 shares have no votes but conversion rights. The filing reported management and other senior personnel held approximately 66% of aggregate voting power, with potential for Baker Brothers-affiliated entities to increase their voting control through conversions.
Important facts for investors to verify
- Confirm subsequent clinical-trial enrollment, safety, efficacy and milestone updates against the stated timelines; interim findings may change as data are finalized.
- Assess cash burn, forecast assumptions and financing needs relative to the stated minimum 12-month runway.
- Review the composition and payment timing of the $10.0 million Biogen milestone, Primatope consideration and other contingent license obligations.
- Monitor manufacturing capacity and supply concentration, particularly reliance on third parties and the terms of the rilonacept supply arrangement.
- Evaluate potential dilution, share conversion and voting-control changes, as well as resale and registration rights affecting the share count.
- Management concluded disclosure controls were effective as of March 31, 2019; verify future filings for any changes, material weaknesses or revised risk disclosures.